Source notes

A celiac blood test can be useful without telling the whole diagnostic story. The paper examines how antibody tests, intestinal biopsies and genetic testing fit together, including situations where each can mislead. The usual starting antibody test, called TTG-IgA, generally has sensitivity and specificity above 90% in the evidence discussed. Yet a positive result alone is not always enough to confirm disease. For selected children, antibody levels above ten times the laboratory's upper normal limit, plus a separate confirmatory antibody test, can support diagnosis without a biopsy under the guidelines reviewed.

That pathway depends on meeting the criteria, not simply receiving any positive blood result. People with low levels of IgA, a type of antibody, may need a different testing approach. Genetic testing also has a particular role: absence of the usual risk variants makes celiac disease unlikely, while their presence does not establish it. Those variants occur in many people who never develop the condition.

How Does This Show Up in Real Life?

If someone feels better after removing gluten, it may seem that the dietary experiment has answered the question. The authors explain that symptom improvement does not distinguish celiac disease from other reasons for feeling better. Starting a gluten-free diet can also make blood tests and intestinal findings return toward normal, complicating later diagnosis. Their practical message is to establish the diagnosis through an appropriate clinical testing pathway before recommending a lifelong restriction. Follow-up poses another problem: feeling better or having negative antibodies does not always mean the intestine has healed, particularly in adults. The paper therefore helps readers understand why clinicians may request additional tests even when symptoms improve. It does not offer a home-testing shortcut or make a gluten challenge appropriate for everyone.

Laboratory assays differ, and their numerical results are not automatically interchangeable. Biopsy quality and interpretation can also introduce error, so the reference test is imperfect. Some studies may overestimate antibody-test accuracy because screening results influence who receives confirmatory testing. Evidence for avoiding biopsy is more established in children, and antibody tests used to monitor recovery were not specifically optimised for that purpose.

The value of this paper lies in showing what each test can and cannot settle. It supports careful interpretation of results within a clinical pathway, with particular attention to diet at testing and the difference between establishing disease and checking recovery afterward.